Document text
Principal Investigator: DAVID E CLEMENTS
Organization: HAWAII BIOTECH, INC.
Fiscal Year: 2023
Award: $204,264
Funding agency: National Institute of Allergy and Infectious Diseases
7. Project Summary/Abstract
The encephalitic New World alphaviruses (NWAVs), consisting of Eastern, Venezuelan and Western Equine
Encephalitis Viruses (EEEV, VEEV and WEEV, respectively), are transmitted by mosquitoes through rodent
or bird hosts and have caused significant periodic epizootic outbreaks in equines and humans in the Americas.
NWAVs can cause severe neurological disease, with fatal encephalitis in up to 70% of cases, and significant
long-term sequelae in survivors. With recent climate changes, geological redistribution of mosquitoes carrying
NWAVs further enhances the potential for future outbreaks. Moreover, concern over their potential use as
bioweapons is well-founded due to their ease of production, high infectivity, ability for aerosolization, and
capacity to induce disease, resulting in select agent classification for E/VEEV. Despite awareness of these
viruses for nearly 100 years, licensed human vaccines against E/V/WEEV remain unavailable for general use.
The development of next-generation vaccines that can safely and effectively protect humans against these
pathogenic alphavirus infections are urgently needed. This project seeks to develop a cross-protective
recombinant subunit E/V/WEEV vaccine based on the linked ectodomain portions of Envelope 2 (E2) and E1
proteins of each NWAV adjuvanted with SLA-LSQ, a novel TLR4 agonist combined with the saponin QS-21
in a liposomal formulation. The proposed approach provides a means to deliver a safe and stable vaccine to
protect against infection by all three NWAVs using a scalable manufacturing platform that, in combination with
a proven Th1/Th2 balanced adjuvant, elicits a robust, efficacious and durable immune response through both
neutralizing and non-neutralizing means. The proposed NWAV vaccine is based on our highly immunogenic
and fully protective pre-clinical E2/E1 candidate vaccine for the closely related Chikungunya virus (CHIKV).
New preliminary data demonstrates that mice immunized with the NWAV E2/E1 subunits generate high NAb
titers to non-select agent strains of E/V/WEEV. The Specific Aims of this project are: 1) evaluate the
immunogenicity and optimize formulations of individual and combined recombinant E/V/WEEV subunit
proteins with SLA-LSQ adjuvant; 2) demonstrate the ability of the candidate vaccine to induce a durable
immune response in mice; and 3) demonstrate the cross-protective efficacy of the candidate vaccine in mice
upon NWAV challenge. Hawaii Biotech and the Baylor College of Medicine will collaborate to develop,
evaluate and advance this novel trivalent NWAV vaccine candidate. The development of a cross-protective
recombinant subunit vaccine to protect against all three pathogenic NWAVs would provide a valuable medical
countermeasure to safeguard against the considerable threat posed by these encephalitic alphaviruses.
Terms: <Aching muscles><Acute><Adjuvant><Aerosols><Agonist><Alpha Virus><Alphavirus><Alphavirus Infections><Americas><Antibody Response><Antibody titer measurement><Antigens><Area><Armed Forces Personnel><Attenuated><Aves><Avian><Awareness><BALB C Mouse><BALB/c><Biotech><Biotechnology><Birds><Blood><Blood Reticuloendothelial System><Body Tissues><Brain><Brain Inflammation><Brain Nervous System><Breakbone Fever Virus><C-terminal><CHIKV><Cell Body><Cells><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cephalalgia><Cephalgia><Cephalodynia><Chikungunya virus><Classification><Collaborations><Combination Vaccines><Combined Vaccines><Cranial Pain><Culicidae><DENV><DNA><Data><Dengue Virus><Dengue fever virus><Deoxyribonucleic Acid><Department of Defense><Development><Disease><Disease Outbreaks><Disorder><Domestic Horse><Dose><Drosophila><Drosophila genus><Early-Stage Clinical Trials><Egypt 101 virus><Encephalitis><Encephalon><Equine><Equine Species><Equus caballus><Equus przewalskii><Family><Fever><Food and Drug Administration><Formalin><Formulation><Glycoproteins><Goals><Group A Arboviruses><Hawaii><Head Pain><Headache><Health><Homolog of Drosophila TOLL><Horses><Human><Immune response><Immunize><Immunological response><Inactivated Vaccines><Inactivated Virus Vaccine><Inbred BALB C Mice><Individual><Infection><Insecta><Insects><Insects Invertebrates><Investigational Drugs><Investigational New Drugs><Killed Vaccines><Laboratories><Licensing><Licensure><Link><Lymphocytopenia><Lymphopenia><Malaise><Measures><Medicine><Mice><Mice Mammals><Military><Military Personnel><Modeling><Modern Man><Mosquitoes><Murine><Mus><Muscle discomfort><Muscle pain><Muscle pain/fibrositis><Muscle sorenesss><Myalgia><Myalgic><Myodynia><Myoneuralgia><Myosalgia><NIAID><National Institute of Allergy and Infectious Disease><Nausea><Nervous System Diseases><Neurologic Disorders><Neurological Disorders><Outbreaks><Pathogenicity><Periodicals><Phase><Phase 1 Clinical Trials><Phase I Clinical Trials><Production><Protein Subunits><Proteins><Public Health><Pyrexia><QS 21><QS-21 Adjuvant><QS21><Recombinant Vaccines><Recombinants><Research><Risk><Rodent><Rodentia><Rodents Mammals><Saponins><Stimulon QS-21 Adjuvant><Subunit Vaccines><Survivors><System><Systematics><TLR4><TLR4 gene><Testing><Time><Tissues><Togaviridae><Togaviruses><Toll Homologue><Transmission><USFDA><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States Food and Drug Administration><VEE virus><VEEV><Vaccines><Venezuelan><Venezuelan Equine Encephalitic Virus><Venezuelan Equine Encephalitis Virus><Venezuelan Equine Encephalomyelitis Virus><Viral><Viral Diseases><Viral Vector><Viremia><Virus><Virus Diseases><Virus-like particle><WEE Virus><WEEV><WNV><West Nile virus><Western Equine Encephalitic Virus><Western Equine Encephalitis Virus><Western Equine Encephalomyelitis Virus><aerosolized><antibody titering><attenuate><attenuates><bio-threat><biological weapon><biothreat><bioweapon><climate change><climatic changes><college><collegiate><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><epizootic><febrile><febris><fruit fly><future outbreak><global climate change><head ache><host response><immune system response><immunogen><immunogenic><immunogenicity><immunoresponse><interest><liposomal formulation><liposomal preparation><long-term sequelae><manufacture><medical countermeasure><military population><nervous system disorder><neurological disease><neutralizing antibody><new vaccines><next generation vaccines><next outbreak><novel><novel vaccines><pandemic concern><pandemic disease preparedness><pandemic planning><pandemic potential><pandemic preparedness><pandemic readiness><pandemic risk><pandemic threat><periodic><periodical><phase I protocol><pre-clinical><pre-clinical study><preclinical><preclinical study><programs><protective efficacy><prototype><response><success><technology platform><technology system><toll-like receptor 4><transmission process><vaccine candidate><vaccine development><vaccine formulation><viraemia><viral infection><viral sepsis><virus infection><virus-induced disease><virus-like nanoparticles><virusemia><viruslike particle>